Just this past week, the South Korean based startup Neurophet had two patent applications published. Both applications (20200214570) and (20200214569) teach similar methods of brain imaging and stimulation using transcranial magnetic stimulation (TMS), a type of neuromodulation. TMS is touted as being a non-invasive, neurological treatment method that doesn't require the use of drugs or surgery. Recently, we have seen neuromodulation be used to increase learning capacity, build muscle faster, treat neurological disorders, and even as a dieting tool!
The proposed method disclosed in the applications first uses MRI technology to image the brain. Using this scan, the patented technology determines the optimal treatment site and dosage of electrical current. Then an electrical charge is created at that site by using a change in a magnetic field of coils appropriately positioned in the device on the head. Although the use of TMS is not novel, Neurophet seems to be more focused on imaging the brain to find the ideal treatment spot for TMS therapy. Last spring, Neurophet had its first two applications publish, both of which teach similar brain imaging techniques specific for neuromodulation.
Neuromodulation has been a hot topic in the AI/Biotech sector in the past year. Just last week we wrote about Elwha LLC. joining the field currently dominated by names such as IBM, Boston Scientific, Psomagen Inc., and Halo Neuro. Although the neuromodulation field is quickly becoming crowded, Neurophet may be able to uniquely position itself as a leader if it continues to build an IP portfolio focused around brain mapping specific to neuromodulation. A startup like Neurophet with an IP portfolio focused on a particular aspect of neuromodulation, may be an attractive acquisition target for one of the other big companies in the sector who lack in this particular area. Make sure to subscribe to Magic Number® AI Biotech/Diagnostics: Neurology Patent Forecast® to stay up to date with the latest patent activity!